Clinically major immune-mediated hematologic adverse reactions (such as hemolytic anemia, aplastic anemia, immune thrombocytopenic purpura) happened at an incidence of much less than 1% in patients who obtained this drug or ended up reported with the usage of other PD-one/PD-L1 blocking antibodies.A Distinctive MedGuide are going to be given to you